Kroger’s retail rollout shifts Zepbound KwikPen distribution from direct-to-consumer to community pharmacy channels, potentially reducing friction in initiation and refills for GLP-1 obesity therapy.
Orphan drugs are forecast to surpass $400 billion in 2032 sales, driven by accelerating rare disease innovation despite regulatory volatility, pricing pressures, and capital competition from ...
SteinCares and Shilpa Biologicals have entered a licensing agreement to commercialize biosimilars in Latin America. Under the deal, SteinCares will manage regional registration and distribution, while ...
A $3 billion China investment targets localized oral solid-dose manufacturing and supply-chain redundancy to support ...
Data provided by BackOps indicates significant performance gains for early adopters across various industries, including retail, grocery, and manufacturing. The platform reportedly accelerates ...
In today’s Pharma Pulse, the FDA launched a unified monitoring system to enable real-time adverse event reporting, and direct-to-employer drug purchasing models are emerging as companies look to ...
In a recent interview, Jay Bregman, founder and CEO of Andel, discussed his company's newly launched direct-to-employer medication platform, which is designed to reduce prescription drug costs by ...
In today's Pharma Pulse, the NCPA warns of a severe cash flow crisis for independent pharmacies under the Medicare Drug Price Negotiation Program, while Norgine commits sixty-seven million dollars to ...
The FDA launched AEMS, a unified platform that replaces fragmented legacy databases to enable real-time adverse event reporting.
In the first part of his Pharmaceutical Commerce interview, Jay Bregman, founder and CEO of Andel, discusses how employers are exploring direct-to-employer drug purchasing models that bypass ...
Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...
In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results